{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"<0.0001","statisticalMethod":"Stratified Log-rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.34","upperLimit":"11.73","value":"9.82"},{"groupId":"OG001","lowerLimit":"5.09","upperLimit":"7.16","value":"5.88"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"221"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Encorafenib + binimetinib + cetuximab. Encorafenib: Orally, once daily. Binimetinib: Orally, twice daily. Cetuximab: Standard of care.","id":"OG000","title":"Phase 3: Triplet Arm"},{"description":"Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab. Cetuximab: Standard of care. Irinotecan: Standard of care. Folinic Acid: Standard of care. 5-Fluorouracil: Standard of care. Following protocol amendment, eligible participants could crossover to receive either triplet or doublet regimen.","id":"OG001","title":"Phase 3:Control Arm"}],"paramType":"MEDIAN","populationDescription":"The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 participants.","reportingStatus":"POSTED","timeFrame":"From randomization to death due to any cause (maximum treatment exposure of 277.4 weeks for triplet arm and 108 weeks for control arm)","title":"(Phase 3) Overall Survival (OS) of Triplet Arm vs. Control Arm - Final Analysis","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Months"}